Viagra Connect will be available without prescription in the UK following a request from drugmaker Pfizer, which is preparing a manufacturing site in France for the demand.
Viagra counterfeiters in Poland imported APIs made in China via the UK, Greece and Romania according to police who shut down a major manufacturing operation last week.
Around 500,000 doses of unlicensed erectile dysfunction (ED) drugs have been seized by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
Drugmakers trying to make blue or green pills for the US market have a new option after the FDA approved a bacteria-derived extract developed by Colorcon for pharma applications.
A generic version of Viagra launched in China contains the same amount of sildenafil citrate for a fraction of the price according to manufacturer Guangzhou Baiyuanshan Pharmaceutical Holdings (GBPH).
Venom from a Brazilian Wandering Spider that ‘wandered’ into a UK household’s shopping basket could treat erectile dysfunction, according to scientists, in one example of drug ingredients being sourced from nature.
Meda has sold a New Jersey facility dedicated to its intra-urethral erectile dysfunction drug Muse as part of a strategic review of its manufacturing network.
Researchers at Alexandria University believe they can solve problems in the delivery of erectile dysfunction medication with the help of nanotechnology.
Administration of Levitra (vardenafil) can increase Herceptin (trastuzumab) delivery to brain metastases, but not surrounding healthy tissue, increasing survival in mice, according to research.
Pfizer will lose patent protection for Viagra in Brazil on June 20 after the Supreme Court (STJ) accepted recommendations by national intellectual property watchdog, the INPI.
Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis, according to research, reducing the side effects that can occur when taking drugs like Viagra.
in-PharmaTechnologist’s periodic round up of developments in the field of drug delivery includes BioDelivery initiating Phase I studies, success for Titan and a novel use for Viagra.
GlaxoSmithKline has opted not to sign an exclusive development
agreement with UK sexual health specialist Futura Health for its
transdermal pain relief product, TPR100.
A nifty spray-on solution could make all the difference for men
plagued with the problem of climaxing too soon, as the product
makes its final thrust in clinical development.
King Pharmaceuticals has ended its alliance with Palatin
Technologies, shortly after regulators raised 'serious concerns'
over the first-in-class erectile dysfunction drug which was the
subject of the collaboration.
In the latest episode of illegal drug trading, a hoard of
unlicensed medicines was seized by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) last week, taken from a London
lock-up containing a stash of various male...
Eli Lilly's once-daily version of its erectile dysfunction
treatment Cialis (tadalafil) has been granted approval by the
European Commission, giving it a head-start over other ED
treatments that are taken on an as-required basis.
UK firm Futura Medical is in the running for a second license
contract for one of its drug delivery platforms after pharma
heavyweight GlaxoSmithKline came to the table to discuss terms.
Packaging giant Rexam has fixed a radio frequency identification
(RFID) chip in pharmaceutical bottles in response to Food and Drug
Administration (FDA) recommendations to make use of the technology
to track products through the supply...
A more spontaneous future for sufferers of erectile dysfunction has
been heralded by the successful completion of a Phase I clinical
trial of a new gene therapy which could provide six months' effect
with a single dose.
Eli Lilly has splashed out $2.1bn (€1.7bn) to buy ICOS, who the
drug giant has been involved in a joint venture with to manufacture
and sell Cialis (tadalafil) - the number two erectile dysfunction
drug behind Viagra (sildenafil).
Surface Logix has commenced Phase I clinical trials for a novel
PDE-5 inhibitor for the treatment of cardiovascular diseases,
including endothelial dysfunction and erectile dysfunction.
US drug company VIVUS as been granted a US patent relating to a new
drug delivery technology that makes it possible to spray drugs onto
the skin and have them taken up into the blood.
China has defended its decision to overturn Pfizer's patent on its
blockbuster drug for erectile dysfunction, Viagra (sildenafil), in
a ruling that was seen as a blow to hopes that the country would
enforce intellectual property...
Much has been written on In-Pharmatechnologist.com about the
impact on China of accession to the World Trade Organisation and
the effects on the domestic pharmaceutical industry of the
resulting need to comply with international intellectual...
Vectura, a UK biotechnology company which is developing an inhaled
alternative to orally acting impotence drugs such as Pfizer's
Viagra (sildenafil), has announced plans to float on the London
stock market.
The next generation of orally-active erectile dysfunction (ED)
drugs took a step closer as researchers isolated a receptor that
could be used as a target of drug treatment without the side
effects associated with the only approved...
The US Food and Drug Administration (FDA) approved 15 New Molecular
Entities in the current year to 30 September, 2003, setting the
stage to outpace last year's registrations by nearly 20 per cent,
says a report from Cutting...
A small Korean biotechnology company maps the binding site of
phosphodiesterase-5, the target of Pfizer's Viagra and other drugs
for erectile dysfunction.
ICOS has entered into a biologics manufacturing agreement with Eli
Lilly, in which the Bothell, Washington-based firm will manufacture
two clinical candidates
Women are becoming the most attractive target audience for
healthcare companies, claims a new report from market analysts
Datamonitor. A combination of increasing Internet access, a general
interest in health issues among women along...
